May 07, 2015 / 3:54 pm, CEST
Acquisition Adds Novel Candidates Including Pre-IND Candidate for Fibrotic Diseases to MorphoSys's Growing Proprietary Portfolio
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V. The transaction brings Lanthio Pharma's lead compound LP2, a novel lanthipeptide in development for diabetic nephropathy and fibrotic diseases to MorphoSys's growing proprietary portfolio. LP2, which will be re-named MOR107, has demonstrated potent angiotensin II type 2 (AT2) receptor-dependent activity in vivo, and is planned to enter clinical trials in 2016. LP2 is the most advanced of four lanthipeptides in Lanthio Pharma's portfolio. In this context, MorphoSys reconfirmed its updated financial guidance issued on March 26, 2015.
Prior to the acquisition, MorphoSys held 19.98% of Lanthio Pharma. MorphoSys will pay EUR 20 million to acquire the outstanding share capital of Lanthio Pharma from the other investors, among them INKEF Capital, BioGeneration Ventures and Hanzepoort. As part of its Innovation Capital initiative, MorphoSys had made its initial equity investment in November 2012 as part of Lanthio Pharma's Series A financing round.
"The acquisition of Lanthio Pharma adds a very attractive compound to our growing proprietary portfolio. The lead compound LP2 has the potential to be a first-in-class treatment for various fibrotic diseases and thus represents a commercially attractive opportunity", commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys. "We have followed developments at Lanthio Pharma closely since the beginning of our relationship. Now is the optimal time for this transaction to secure the development of this potentially exciting asset."
"We have enjoyed a very productive relationship with Lanthio Pharma since 2012 and are therefore delighted to work even closer with Lanthio's experienced staff on developing LP2 and identifying additional novel innovative therapeutic peptides," said Jens Holstein, Chief Financial Officer of MorphoSys AG. "Today's news marks another milestone for our Innovation Capital initiative that led to this acquisition. We will continue to look for opportunities to invest and collaborate with biopharmaceutical start-ups to strengthen our drug development capabilities and enrich our proprietary drug portfolio."
Dr. Heinz Schwer, Chief Executive Officer of Lanthio Pharma, added: "The acquisition of Lanthio Pharma with its exciting preclinical programs is the final conclusion of a trustful business relationship over three years. We very much look forward to working within MorphoSys to advance our programs and act as an innovative source of new treatment options for patients."
"As the largest shareholder in Lanthio Pharma, we want to congratulate the founders, the management and all employees. This transaction provides the opportunity to further exploit the potential of the lanthipeptide technology," noted Dirk Kersten, Managing Director of INKEF Capital. "We would like to thank MorphoSys for their strong support during the past years. We look forward to continue working with MorphoSys and its Innovation Capital initiative."
Lanthipeptides comprise a novel class of therapeutics with high target selectivity and improved drug-like properties. Lanthio Pharma's approach can be used to identify peptides which are selective for a specific disease target and to stabilize their structural conformation for optimal receptor binding. The high specificity that can be achieved opens up new therapeutic applications, potentially providing drugs for indications not usually targeted with antibodies. In addition to intravenous administration, therapeutic plasma levels of lanthipeptides can potentially be achieved via oral, pulmonary or subcutaneous delivery.
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Associate Director Corporate Communications & IR
Manager Corporate Communications & IR
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404